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1, Noël Knops1,2, Sante Princiero Berlingerio1, Oyindamola
Christiana Adebayo1, Celien Lismont3, Dirk J. Kuypers4, Elena Levtchenko1,2, Lambert
P. van den Heuvel1,5☯, Marc Fransen3☯*
1 Laboratory of Pediatric Nephrology, Department of Growth and Regeneration, University of Leuven,
Leuven, Belgium, 2 Department of Pediatric Nephrology and Solid Organ Transplantation, University
Hospitals Leuven, Leuven, Belgium, 3 Laboratory of Peroxisome Biology and Intracellular Communication,
Department of Cellular and Molecular Medicine, University of Leuven, Leuven, Belgium, 4 Department of
Nephrology and Renal Transplantation and Department of Microbiology, Immunology and Transplantation,
University of Leuven, Leuven, Belgium, 5 Translational Metabolic Laboratory and Department of Pediatric
Nephrology, Radboud University Medical Center, Nijmegen, The Netherlands
☯ These authors contributed equally to this work.
* marc.fransen@kuleuven.be
Abstract
The calcineurin inhibitors (CNI) cyclosporine A and tacrolimus comprise the basis of immu-
nosuppressive regimes in all solid organ transplantation. However, long-term or high
exposure to CNI leads to histological and functional renal damage (CNI-associated neph-
rotoxicity). In the kidney, proximal tubule cells are the only cells that metabolize CNI and
these cells are believed to play a central role in the origin of the toxicity for this class of
drugs, although the underlying mechanisms are not clear. Several studies have reported
oxidative stress as an important mediator of CNI-associated nephrotoxicity in response to
CNI exposure in different available proximal tubule cell models. However, former models
often made use of supra-therapeutic levels of tissue drug exposure. In addition, they were
not shown to express the relevant enzymes (e.g., CYP3A5) and transporters (e.g., P-gly-
coprotein) for the metabolism of CNI in human proximal tubule cells. Moreover, the used
methods for detecting ROS were potentially prone to false positive results. In this study,
we used a novel proximal tubule cell model established from human allograft biopsies that
demonstrated functional expression of relevant enzymes and transporters for the disposi-
tion of CNI. We exposed these cells to CNI concentrations as found in tissue of stable solid
organ transplant recipients with therapeutic blood concentrations. We measured the gluta-
thione redox balance in this cell model by using organelle-targeted variants of roGFP2, a
highly sensitive green fluorescent reporter protein that dynamically equilibrates with the
glutathione redox couple through the action of endogenous glutaredoxins. Our findings
provide evidence that CNI, at concentrations commonly found in allograft biopsies, do not
alter the glutathione redox balance in mitochondria, peroxisomes, and the cytosol. How-
ever, at supra-therapeutic concentrations, cyclosporine A but not tacrolimus increases the
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ratio of oxidized/reduced glutathione in the mitochondria, suggestive of imbalances in the
redox environment.
Introduction
Cyclosporine A (CsA) and tacrolimus (Tac), two calcineurin inhibitors (CNI), are globally rec-
ognized as the cornerstone of immunosuppressive therapy after solid organ transplantation
and, despite their different chemical structure, both CNIs exert their immunosuppressive
action via inhibition of the T-cell response. In addition, CNI’s are used for many other indica-
tions outside the realm of solid transplantation such as nephrotic syndrome, inflammatory
bowel disease and different rheumatic diseases. However, their chronic use causes renal toxic-
ity, the so-called CNI-associated nephrotoxicity (CNIT), manifested by interstitial fibrosis,
afferent arteriolar hyalinosis, and the loss of renal function [1, 2]. The mechanisms of CNIT
are largely unknown, but it has been reported that systemic exposure to CNI increases the for-
mation of free radicals (e.g., superoxide) and other reactive oxygen species (ROS) (e.g., H2O2),
most probably due to vasoconstriction-induced hypoxia [3]. At kidney level, proximal tubule
cells (PTC) are a metabolically active cell type that are exposed to high drug concentrations
due to active and passive take-up from the blood and filtrate and hence are the most prone to
drug-induced injury. They are the only renal cells that metabolize CNI and multiple studies
have linked common variations in the genes encoding the CYP3A5 enzyme (CYP3A5, Entrez
Gene ID: 1577) and the P-glycoprotein (P-gp) efflux transporter (ABCB1, Entrez Gene ID:
5243), responsible for CNI metabolism in the PTC, with the risk for developing CNIT [4–8].
Redox homeostasis plays an important role in maintaining health of organisms and, at
physiological levels, ROS such as H2O2 often act as crucial mediators of various cellular func-
tions. However, imbalances in ROS can lead to detrimental effects on cellular and organismal
health [9]. The type and concentration of produced ROS as well as their location and elimina-
tion kinetics are important factors in determining the magnitude of the physiological and
pathological effects [10]. Subcellular compartments such as mitochondria, peroxisomes, the
endoplasmic reticulum, and membrane-bound NADPH oxidases are major locations of ROS
production [11]. Reduced glutathione (GSH) is a tripeptide that, among other functions, sup-
ports antioxidant reactions and protects cells from oxidative insults [10]. While in physiologi-
cal conditions the concentration of GSH is 10 to 100-fold higher than that of oxidized
glutathione (GSSG) [12], in pathophysiological states, a series of enzymatic reactions between
the endogenous glutaredoxins and GSH can lead to higher amounts of GSSG. Therefore, the
ratio of GSH/GSGG can serve as an indicator of redox changes that may lead to oxidative
stress [12, 13].
Previous research has shown the involvement of oxidative stress in several human and ani-
mal PTC models in relation to CNI exposure, thus implying that tackling the phenomenon of
increased ROS might reduce CNIT [14–18]. However, the majority of these studies have used
concentrations of CNI that are 100-200-fold higher than concentrations reached in the kidney
under clinically targeted blood trough levels, hindering the clinical relevance of these findings.
In addition, these models have not been demonstrated to express the relevant enzymes and
transporters for the metabolism/efflux of CNI [19]. Moreover, capturing dynamic changes in
the glutathione redox couple in PTC in response to the dynamics of intracellular CNI exposure
and metabolism necessitates a controlled real-time system. In this work, we have filled the
above-mentioned gaps by assessing the glutathione redox balance at the subcellular level in
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real time and by using a validated model for studying in vitro CNI metabolism. The concentra-
tion range of CNI used was derived from data of human liver and kidney tissue homogenates
obtained during protocol biopsies [20–23]. In addition, we have tested supra-therapeutic con-
centrations of CNI, as in aforementioned studies, to detect potential differences between our
state-of-the-art methodology and methods previously published.
Materials and methods
Cell culture
Conditionally immortalized proximal tubule cells (ciPTC) were derived from allograft biopsies
and the allograft genotype for CYP3A5 (rs776746) and ABCB1 (rs1045642) was determined on
immortalized cells as described elsewhere [24]. ciPTC with the specific genotype of CYP3A5
�3/�3 and ABCB1 3435 TT were selected for CNI incubations, given their most pronounced
profibrotic effects in response to Tac exposure in vitro in pilot experiments (data submitted for
publication). The concentration range of CNI used was derived from data of human liver and
kidney tissue homogenates obtained during protocol biopsies corresponding to 15 and 0.3 μg/
mL for CsA and Tac, respectively [20–23]. Cells were cultured at 33˚C in a humidified 5% CO2
incubator in DMEM-HAM’s F-12 medium (Biowest) supplemented with insulin-transferrin-
selenium (Sigma-Aldrich; 5 ng/mL), hydrocortisone (Sigma-Aldrich; 36 ng/mL), epidermal
growth factor (Sigma-Aldrich; 10 ng/mL), triiodothyronine (Sigma-Aldrich; 40 pg/mL), 10%
v/v fetal bovine serum, penicillin (Gibco; 100 U/mL), and streptomycin (Gibco; 100 U/mL).
For redox imaging, approximately 120,000 ciPTC were seeded into FD35 FluoroDishes
(World Precision Instruments). One day later, the FluoroDishes were transferred from a 33˚C
to a 37˚C incubator to allow differentiation for 7 days before being transfected. One day post-
transfection, the medium was replaced with fresh medium supplemented with tacrolimus
(Tac; Merck), cyclosporine A (CsA; Merck), L-buthionine-sulfoximine (BSO; Sigma), and/or
dimethyl sulfoxide (DMSO, Sigma). DMSO was maintained at 0.1% v/v in all conditions,
except for the 50 μg/mL Tac (0.5% v/v) and BSO control (0% v/v) conditions. Redox measure-
ments were performed 24-h and 48-h post-treatment (after measurement, the media were
replaced with fresh medium). 1 mM hydrogen peroxide (H2O2) in PBS was used as a positive
control. For metabolomics analysis, 200,000 ciPTC were seeded in 6-well plates (VWR). One
day later, the plates were transferred from a 33˚C to a 37˚C incubator for at least 7 days to
allow differentiation. Next, the medium was replaced with fresh medium supplemented with
Tac (Merck), CsA (Merck), BSO (Sigma), or 0.1% v/v DMSO.
Ethics statement
The study protocol was approved by the Institutional Ethical Board (B32220109632 and
B322201317188) and written consent was obtained from all study subjects or their parents.
The study is registered with the clinical trial number of NCT01767350.
Plasmid isolation and transfection
Prior to transfection, the plasmids encoding cytosolic roGFP2 (pMF1707) [25], peroxisomal
roGFP2 (pMF1706) [25], mitochondrial roGFP2 (pMF1762) [25], cytosolic roGFP2-Orp1
(pMF1834) [26] or mitochondrial roGFP2-Orp1 (pMF1833) [26] were purified using the Pure-
Link™ HiPure Plasmid Midiprep Kit (ThermoFisher Scientific) according to the manufactur-
er’s protocol. Briefly, bacterial cultures were pelleted (4,000 x g, 10 min, room temperature)
and resuspended in RNAse A-containing resuspension buffer. After addition of lysis buffer,
the samples were gently mixed. Next, precipitation buffer was added and the samples were
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centrifuged (12,000 x g, 10 min, room temperature). The cleared supernatants were loaded
onto pre-equilibrated PureLink™ HiPure Midi Columns. After draining, the columns were
washed twice with wash buffer and the plasmid DNA was subsequently eluted with elution
buffer. Next, the plasmids were precipitated with isopropanol and pelleted by centrifugation
(12,000 x g, 30 min, 4˚C). Finally, the pellets were resuspended in 70% v/v ethanol, re-pelletted
by centrifugation (12,000 x g, 5 min, 4˚C), air-dried, and resuspended in TE buffer. The puri-
fied plasmids were used to transfect ciPTC using the JetPRIMER reagent (PolyPlus-transfec-
tion). Therefore, 2 μg of each purified plasmid was mixed with 200 μL of Jetprime buffer,
vortexed for 10 seconds, and spun down. Next, 4 μL of the JetPRIME reagent was added, and
the mixture was vortexed and briefly spun down again. Finally, after incubation for 10 min at
room temperature, the mixture was added to ciPTC pre-seeded in FluoroDishes and cultured
in serum-containing medium.
Fluorescence microscopy and redox imaging
Fluorescence was evaluated by using a previously described microscopic setup [27] or by using
a motorized inverted IX-81 microscope, controlled by cellSens Dimension software (version 2)
and equipped with (i) a temperature, humidity, and CO2-controlled incubation chamber, (ii) a
CoolLED pE-4000 illumination system, (iii) a 100x Super Apochromat oil immersion objective,
(iv) the band-pass excitation filters D405/20x and BP470-495 (v) the barrier filter BA510-550
(vi) a dichromatic mirror with a cut-off 505 nm, and (vii) a DP73 high-performance Peltier-
cooled digital color camera (Olympus Belgium). Ratiometric measurements of roGFP2 or
roGFP2-Orp1 oxidation were performed as described previously [28]. Briefly, the camera expo-
sure times were set to a ratio of 1:2 to acquire images at the 400 (for GSSG) and 480 (for GSH)
nm excitation wavelengths, respectively. Random fields of cells were imaged with the same 400/
480 nm exposure time ratios, and images having signal intensities within the linear dynamic
range of the camera were retained for analysis. The cellSens image analysis software (Olympus
Belgium) was used to quantify the relative fluorescence intensities of roGFP2 or roGFP2-Orp1
(recorded around 510 nm) at 400 nm and 480 nm excitation. For the background subtraction,
regions-of-interest were selected on neighboring cell-free areas. The 400/480 nm fluorescence
response ratios of the GSH/GSSG sensor were measured and normalized to the average value of
the corresponding vehicle values, which were set to 100 arbitrary units (AU).
Metabolomic analysis of glutathione species
Metabolite extraction was performed essentially as described elsewhere [29]. Briefly, the cells
were washed once with ice cold 0.9% w/v NaCl solution, and metabolite extraction was started
by addition of 80% v/v methanol and 0.2% w/v of myristic acid-d27 (internal standard). Five
minutes later, the cells were scraped, collected in a new tube, and centrifuged at 20,000 x g for
10 min (at 4˚C). The supernatants were transferred to a new vial for mass spectrometry (MS)
analysis, and the pellets were used for protein quantification using the Pierce bicinchoninic
acid assay kit (ThermoFisher). Ten μL of each sample was injected into a Dionex UltiMate
3000 liquid chromatography system (ThermoFisher Scientific) equipped with a C18 column
(Acquity UPLC -HSS T3 1. 8 μm; 2.1 x 150 mm, Waters) coupled to a Q Exactive Orbitrap
mass spectrometer (ThermoFisher Scientific) operating in negative ion mode. A step gradient
was carried out using solvent A (10 mM tributylamine and 15 mM acetic acid) and solvent B
(100% methanol). The gradient started with 0% of solvent B and 100% solvent A and remained
at 0% B until 2 min post-injection. A linear gradient to 37% B was carried out until 7 min, and
then the concentration of solvent B was linearly increased to 41% from 7 to 14 min. Between
14 and 26 min, the gradient increased to 100% of B and remained at 100% B for 4 min. At 30
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min, the gradient returned to 0% B, and chromatography was stopped at 40 min. The flow was
kept constant at 250 μL/min at the column was placed at 25˚C throughout the analysis. The
MS operated in full scan mode (m/z range: [70–1050]) using a spray voltage of 3.2 kV, capillary
temperature of 320˚C, sheath gas at 10.0 bar, auxiliary gas at 5.0 bar. The automatic gain con-
trol target was set at 3e6 using a resolution of 140,000, with a maximum ion trap fill time of
512 ms. Data collection was performed using the Xcalibur software (ThermoFisher Scientific).
The data analyses were performed by integrating the peak areas using the EL-MAVEN on
Polly interface (Elucidata). The raw abundance values of GSSG and GSH were first normalized
to the internal standard myristic acid-d27 and subsequently to the total amount of protein.
The GSSG/GSH ratios were obtained by dividing the normalized values of GSSG and GSH.
Cell viability assay
Cell viability was evaluated with the PrestoBlue™ HS cell viability reagent (Invitrogen), a resa-
zurin-based assay that utilizes the mitochondrial metabolic capacity to reduce resazurin, the
indicator dye, to resorufin, a strongly fluorescent compound. In brief, ciPTC were trypinized
and seeded at a density of 5,000 cells per well in a 96-well black clear-bottom culture plate
(Grenier). The cells were first incubated at 33˚C for 8–16 hours to allow attachment, and sub-
sequently transferred to 37˚C for 7–10 days to allow differentiation. Next, the cells were
exposed to the test compounds for 48 h (final volume: 100 μL). Thereafter, 10 μL of the Presto-
Blue™ HS cell viability reagent was added per well, and the cells were further incubated in the
dark at 37˚C for 1 h. Afterwards, resorufin fluorescence was measured using a scanning fluo-
rescence microplate reader (Molecular Devices, Sunnyvale, CA, USA) at excitation/emission
wavelengths of 560/590 nm. Three independent experiments were performed with four techni-
cal replicates each. The values were normalized to the non-treated cells and presented as the
percentage of cell viability.
Normalization and statistical analysis
Due to unforeseen configuration changes in the live-cell imaging setup during the course of
our experiments, all 400/480 nm ratiometric responses were normalized to the average of the
corresponding control condition (DMSO or basal), which was set to 100 arbitrary units (AU).
Every graph represents the combined data of 3 independent experiments, unless stated other-
wise. The confidence interval was set at 95% for all analyses and the null hypothesis was
rejected with a p-value<0.05.
Shapiro-Wilk test was used for the assessment of normality. One-way ANOVA was used
for detecting the differences between more than two groups for normally distributed data and
Kruskal-Wallis for non-normally distributed data. Two-tailed paired one-sample t-test and
Wilcoxon test were used for detecting the differences of two groups for normal and non-nor-
mally distributed data, respectively. One-tailed unpaired one-sample t-test with Welch correc-
tion was used for the differences between the percentage of cells with mitochondrial
fragmentation. PRISM version 9 was used for statistical analyses.
Results
Exposure of ciPTC to therapeutic concentrations of CsA or Tac does not
induce significant changes in the mitochondrial, peroxisomal, or cytosolic
glutathione redox balance
To monitor potential changes in the subcellular glutathione redox balance in ciPTC exposed
to therapeutic concentrations of CNI found in kidney tissue in vivo (i.e. 15 μg/mL of CsA and
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0.3 μg/mL of Tac), we employed targeted variants of roGFP2, a highly responsive GSH/GSSG
sensor. As depicted in Fig 1, exposure of ciPTC to the above-mentioned concentrations of CsA
or Tac did not significantly alter the glutathione redox balance in mitochondria (panels A and
B), peroxisomes (panels C and D), or the cytosol (panels E and F), neither at 24 h nor at 48 h
of incubation (the mean values of each condition, expressed as arbitrary units and compared
to the corresponding control group, are listed in S1 Table). To confirm the responsiveness of
roGFP2 to changes in the intracellular glutathione redox balance, we exposed ciPTC express-
ing cytosolic or mitochondrial roGFP2 to 1 mM external H2O2 for 15 min. As shown in S1 Fig
and S1 Table, such treatment resulted in a significant increase in the GSSG/GSH ratio, both in
the cytosolic and mitochondrial compartments.
Exposure of ciPTC to therapeutic concentrations of CsA or Tac does not
induce significant changes in the global glutathione redox balance
To confirm and extend our roGFP2-based measurements, we also carried out a comparative
metabolic analysis of GSH and GSSG in ciPTC with or without therapeutic concentrations of
CsA or Tac. As a positive control for glutathione depletion, we included a condition in which
the cells were treated with 0.5 mM M-buthionine-S,R-sulfoximine (BSO), a potent glutathione
(GSH)-depleting agent that inhibits γ-glutamylcysteine synthetase [30]. From these experi-
ments, it is clear that therapeutic CNI concentrations do not induce alterations in the
Fig 1. Mitochondrial, peroxisomal, and cytosolic glutathione redox ratios in ciPTC exposed to therapeutic tissue
concentrations of CNI for 24 and 48 h. CiPTC expressing mitochondrial, peroxisomal, or cytosolic roGFP2 were
exposed to (A, C, E) vehicle (0.1% v/v DMSO) or 15 μg/mL of cyclosporin A (CsA) and (B, D, F) vehicle (0.1% v/v
DMSO) or 0.3 μg/mL tacrolimus (Tac). Each graph summarizes the results of 3 independent experiments, depicting
the median and standard deviation (as error bars). Every individual symbol represents the average ratio of 10
measurements within one cell (at least 8 randomly chosen cells were analyzed per experiment). Kruskal-Wallis (KW)
or One-way ANOVA (OWA) test were used to calculate p-values: (A) 0.8 (KW); (B) 0.4 (KW); (C) 0.2 (OWA); (D) 0.6
(OWA); (E) 0.8 (OWA); and (F) 0.2 (KW).
https://doi.org/10.1371/journal.pone.0250996.g001
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glutathione redox balance, neither at the GSH or GSSG level nor in the GSSG/GSH ratio (Fig
2). However, treatment of ciPTC with 0.5 mM BSO decreased the intracellular glutathione lev-
els dramatically within 48 h (Fig 2), a finding in agreement with a previous study [31]. In this
context, it has to be mentioned that we also investigated the responsiveness of cytosolic
roGFP2 to BSO, both in the absence or presence of therapeutic CNI concentrations (S2 Fig).
Importantly, BSO in itself did not cause any significant changes in the oxidation state of the
cytosolic glutathione redox sensor. In addition, there were no synergistic effects between BSO
and CNI. At first sight, the lack of responsiveness of cytosolic roGFP2 to BSO-induced gluta-
thione depletion may be surprising. However, similar findings have been reported by others
[31]. In addition, it can be expected that the relationship between GSH deficiency and subcel-
lular oxidation may vary depending on cell type [25, 32, 33], the subcellular localization of the
sensor [31], and the dose and duration of BSO treatment [34].
Exposure of control or glutathione-depleted ciPTC to therapeutic CNI
concentrations does not induce significant changes in cell viability
Given that glutathione depletion is widely used to sensitize cells to oxidative insults, we next
investigated whether or not treatment of ciPTC with BSO sensitized these cells to the potential
cytotoxic effects of CNI. Interestingly, neither treatment with 0.5 mM BSO nor therapeutic or
supra-therapeutic doses (166-fold higher than the therapeutic tissue concentrations) of
Tac, alone or in combination, reduced cell viability significantly (Fig 3A). In contrast,
Fig 2. Metabolomic analysis of glutathione species in ciPTC exposed to CNI or BSO. CiPTC were exposed for 48 h
to therapeutic concentrations of CNI (15 μg/mL of cyclosporin A (CsA), 0.3 μg/mL of tacrolimus (Tac), vehicle (0.1%
v/v DMSO) or 0.5 mM L-buthionine-sulfoximine (BSO). Changes in the relative levels of (A) GSH, (B) GSSG, and (C)
GSSG/GSH ratios, all expressed as percentages of the average of the corresponding control samples, were determined
as described in the Materials and Methods section. Given that, in the 0.5 mM BSO condition, the GSSG levels were
below the detection limit, no GSSG/GSH ratio could be calculated. Each graph depicts the mean and standard error (as
error bars) of 3 replicates (indicated as filled squares) within one experiment. Data of the control (vehicle) and treated
conditions were statistically compared using a paired t-test, and statistical differences are marked (�, p< 0.05; ��,
p< 0.01).
https://doi.org/10.1371/journal.pone.0250996.g002
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supra-therapeutic concentrations (3.3-fold higher than the therapeutic tissue concentrations)
of CsA promoted cell death, both in control and glutathione-depleted cells (Fig 3B). In sum-
mary, these findings strongly indicate that therapeutic CNI tissue concentrations do not cause
redox stress in GSH-depleted ciPTC, at least not in the time window considered here.
Exposure of ciPTC to supra-therapeutic concentrations of CsA, but not
Tac, results in a small but significant increase in the mitochondrial redox
balance
To put our results in perspective, we compared our approach with that of other recent studies
in human PTC [17, 18], and monitored how supra-therapeutic concentrations (50 μg/mL) of
Fig 3. Cell viability in glutathione-depleted ciPTC exposed to CNI. CiPTC were exposed for 48 h to (A) 0.3 μg/mL
of tacrolimus (Tac (L); vehicle: 0.1% v/v DMSO), 50 μg/mL Tac (Tac (H); vehicle: 0.5% DMSO), 0.5 mM L-
buthionine-sulfoximine (BSO; vehicle: basal medium), or a combination of each Tac concentration with BSO (vehicle
conditions: 0.1% and 0.5% DMSO, respectively); or (B) 15 μg/mL cyclosporin A (CsA (L); vehicle: 0.1% v/v DMSO),
50 μg/mL CsA (CsA (H); vehicle: 0.1% v/v DMSO), 0.5 mM BSO (vehicle: basal medium) or a combination of each
CsA concentration with BSO (vehicle conditions: 0.1% v/v DMSO). Resorufin fluorescence values for every condition
are expressed as percentages of the average of the corresponding control samples as described in the Materials and
Methods section. Each graph represents the mean of 3 independent experiments. The large and small horizontal lines
show the median and standard errors, respectively. Paired t-test was used to detect significant reduction in cell
viability. �, p-value< 0.05; ��, p-value< 0.01.
https://doi.org/10.1371/journal.pone.0250996.g003
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CsA and Tac, which were respectively 3.3- and 166-fold higher than the maximum therapeutic
tissue concentrations, affected the mitochondrial glutathione redox balance. These experi-
ments demonstrated a small (1.1-fold) but significant increase in the GSSG/GSH ratio at
50 μg/mL CsA compared to vehicle. Exposure to the same concentration of Tac, however, did
not cause such a significant change (Fig 4 and S1 Table). Note that these observations are in
line with the data presented in Fig 3.
During our experiments, we noticed that conditions in which ciPTC were treated with
higher concentrations of DMSO or supra-therapeutic CNI resulted in enhanced mitochondrial
fragmentation, even after 24 h of treatment (Fig 5, compare panels A and B). Further analysis
demonstrated an approximately 2-fold increase in the percentage of cells with fragmented
mitochondria in 0.5 vs. 0.1% v/v DMSO (Fig 5C). In addition, supra-therapeutic concentra-
tions of both CNI in comparison to their vehicle counterparts yielded a 2-3-fold increase in
the percentage of cells with mitochondrial fragmentation (Fig 5C). The numerical data are
provided in S2 Table.
Discussion
CNIs are an important class of immunosuppressive medication but are unfortunately associ-
ated with nephrotoxicity, of which the underlying pathophysiological mechanism is not well
understood [1, 2]. Earlier studies have suggested that CNIT can be linked to oxidative stress in
PTC, an observation that may offer new perspectives to reduce the burden of CNIT by antioxi-
dant treatment. However, these studies were hampered due to the unavailability of a suitable
renal cell model and the use of supra-therapeutic CNI exposure (for examples, see S3 Table) to
mimic the presence of oxidative stress in relation to the in vivo situation. Our study is distinc-
tive with respect to the ability of our PTC model to metabolize CNIs and due to the use of CNI
concentrations obtained from allograft tissues, which will lead to totally different levels of
intracellular exposure to the parent CNI and their metabolites [24]. Within this context, we
have measured the glutathione redox balance in mitochondria, peroxisomes, and the cytosol
of donor-derived ciPTC exposed to both therapeutic and supra-therapeutic concentrations of
CNI. Apart from the validated cell-model, the novelty of this study lies in the use of organelle-
targeted variants of roGFP2, a ratiometric fluorescent sensor for measuring changes in the glu-
tathione redox balance in real-time in a setting controlled for temperature and CO2. The
Fig 4. Mitochondrial glutathione redox ratios in ciPTC exposed to supra-therapeutic concentrations of CNI.
CiPTC expressing mitochondrial roGFP2 were exposed for 24 h to 50 μg/mL CsA, 50 μg/mL Tac, or vehicle (for CsA:
0.1% v/v DMSO; for Tac: 0.5% v/v DMSO). The results are derived from 3 independent experiments, depicting the
median and standard deviation (as error bars). Every individual symbol represents the average ratio of 10
measurements within one cell (at least 8 randomly chosen cells were analyzed per experiment). The Wilcoxon test
(WT) and paired t-test (PTT) were used to calculate p-values: �, 0.02 (WT); non-significant (NS), 0.2 (PTT).
https://doi.org/10.1371/journal.pone.0250996.g004
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radiometric measurement is particularly interesting, as it eliminates the variations caused by
photobleaching, sensor concentration, variable cell thickness, and nonuniform sensor distri-
bution [28]. In addition, we have monitored the GSH/GSSG changes.
In contrast with previous studies, this work demonstrates that exposure to CsA or Tac at
therapeutic concentrations does not alter the mitochondrial, peroxisomal, and cytosolic gluta-
thione redox balance in ciPTC after 24 and 48 h. However, treatment of these cells with a
supra-therapeutic concentration of CsA, but not Tac, did increase the glutathione redox state
in mitochondria, a phenomenon indicative of induction of oxidative stress. Similar findings
were observed when targeted variants of roGFP2-Orp1, a highly responsive H2O2 sensor, was
used instead of roGFP2 (S3 and S4 Figs, S4 Table). However, given that (i) this sensor also
responds to changes in the glutathione redox balance, and (ii) the responses of roGFP2 and
roGFP2-Orp1 are similar in ciPTC exposed to therapeutic (compare Fig 1 and S3 Fig) and
supra-therapeutic (compare Fig 4 and S4 Fig) CNI concentrations, these findings should be
interpreted with caution and rather be considered as independent replicas.
Exposure of ciPTC to higher concentrations of vehicle (0.5% v/v DMSO) or supra-thera-
peutic CNI concentrations resulted in a significantly higher percentage of cells with frag-
mented mitochondria, a phenomenon that can potentially lead to excess ROS production and
cytochrome c-dependent apoptosis [35]. These morphological observations provide another
evidence on the importance of performing in vitro studies within therapeutic CNI ranges that
also enable the use of less than 0.5% v/v DMSO. The findings in this study are in line with clin-
ical studies demonstrating that, although the act of solid organ transplantation can transiently
induce oxidative stress in the allograft tissue through ischemia-reperfusion injury in the first
Fig 5. Mitochondrial morphology in ciPTC exposed to DMSO and CNI. ciPTC expressing mitochondrial roGFP2
were exposed for 24 h to 0.1% v/v DMSO (vehicle for CsA and 0.3 μg/mL Tac), 0.5% v/v DMSO (vehicle for 50 μg/mL
Tac), 15 μg/mL CsA, 50 μg/mL CsA, 0.3 μg/mL Tac, or 50 μg/ml Tac. Representative images of ciPTC with (A)
elongated or (B) fragmented mitochondria. Scale bar, 10 μm. (C) Percentage of cells with fragmented mitochondria. �,
p-value< 0.05 (unpaired t-test with Welch correction), n: 27-39-45-23-41-29. Exact p-values are listed in S2 Table. The
results are depicted as the mean and standard error (error bars). Every symbol represents the percentage of cells from
one independent experiment (n = 3).
https://doi.org/10.1371/journal.pone.0250996.g005
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period after transplantation [36], this condition can be corrected by the antioxidant systems
and improvements in lipoprotein metabolism [36–38].
Our data regarding the effect of a therapeutic concentration of CsA contradict two previous
studies in human PTC that reported CsA-induced increase of ROS as a mediator of apoptosis
and nephrotoxicity at an even lower concentration (8 μg/mL) [14, 16]. One possible explana-
tion for such contradiction could be the validated capacity for CNI metabolism in our PTC
model which can result in alternate intracellular levels of the parent compound or its metabo-
lites responsible for ROS generation. The toxic effects of Tac metabolites are still not estab-
lished, however, several metabolites of CsA are known to be nephrotoxic [39–41]. Another
explanation could be the use of non-reversible (chemi)florescent probes for detection of ROS
in these studies. Despite the common use of these chemical probes, they are highly light-sensi-
tive and their irradiation by light can lead to irreversible artefacts in imaging and overestima-
tion of ROS [42, 43]. Such overestimation could also be an explanation for increased ROS at
50 μg/mL Tac in other papers [15, 17, 44], contrary to stable glutathione redox balance with
the same concentration of Tac using the highly sensitive roGFP2 in this work. In this context,
it is relevant to point out that some researchers use fusion constructs between roGFP2 and glu-
taredoxin (Grx) to promote rapid and specific equilibration between the dithiol-disulfide pairs
of roGFP2 and the local glutathione pool. However, given that (i) others have demonstrated
that, inside cells, roGFP2 by itself can already rapidly equilibrate with the local glutathione
pool [45], (ii) we have previously shown that all roGFP2 reporters used in this study can
respond quickly and reversibly to local changes in redox state in response to transient oxida-
tive insults and intermittent starvation [25] and (iii) in this study, the time window between
CNI treatment and roGFP2 measurements is one or two days, a period sufficiently long to
ensure equilibration between the roGFP2 sensors and the local glutathione redox couple, it is
safe to state that our approach yields reliable results. This claim is further strengthened by our
comparative metabolic analysis of GSH and GSSG in ciPTC treated or not with therapeutic
CNI concentrations (Fig 2) as well as our observation that such treatments do not impact cyto-
solic and mitochondrial H2O2 levels (S3 Fig).
The different outcomes of the previous studies and these investigations can also lie in the
kinetics of ROS measurement. We selected the time points based on the previous studies that
had observed induction of oxidative stress in PTC as early as 24 h [14, 16]. It remains specula-
tive how these time points would correlate with the chronic exposure of CNI after transplanta-
tion. Nonetheless, our selected kinetics are in accordance with the findings on the increase of
the CNI-induced toxicity markers after 2–3 days in ciPTC (data submitted for publication).
The importance of the time of measurement is evident from in vivo studies, in which daily
consumption of CNI for longer periods increases the markers of oxidative stress in the blood
or urine of animals [40, 46–48]. However, besides a direct effect of CNI on the PTC, the find-
ings from in vivo studies can also reflect the vasoconstrictive effects of CNI in inducing ische-
mia and hypoxia [3]. This hypoxic effect in the interplay between the PTC and endothelial
cells is absent in our study and other in vitro studies. However, although animal studies could
be important in unraveling the mechanisms of kidney toxicity by CNI, the idiosyncratic differ-
ences in the expression of relevant actors of intracellular metabolism between species and the
translation of relevant drug dosages from the human situation makes their interpretation diffi-
cult. Furthermore, clinical studies do not support a major role of oxidative stress in patients
after transplantation [37, 38].
Our metabolic analysis of ciPTC treated or not with 0.3 μg/ml Tac or 15 μg/ml CsA provide
strong evidence that exposure of these cells to therapeutic CNI concentrations do not signifi-
cantly deregulate the glutathione redox balance, neither at the GSH or GSSG level nor in the
GSSG/GSH ratio (Fig 2). However, previous research has demonstrated lower reduced
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glutathione levels after exposure of human kidney 2 (HK-2) cells to 10 μM of CsA [16] or pig
kidney proximal tubule (LLC-PK1) cells to 50 μM of Tac [49] for 24 h, which can point toward
the sensitivity of these cells to oxidative insults. Moreover, CsA and Tac can differentially regu-
late the expression of P-gp as a protective response. Hauser et al. showed that, at 0.08–1.28 μg/
mL CsA and 0.5–1 μg/mL Tac, CsA (but not Tac) increases the expression of P-gp in a concen-
tration-dependent manner [50]. This differential regulation can also affect the response of cells
to oxidative stimuli [51].
In conclusion, this study shows the importance of selecting the appropriate model and
methods for studying drug toxicity and is the first to examine the organelle-targeted redox
state of PTC in relation to CNI exposure as a potential contributing factor to the development
of CNIT. By combining essential determinants of redox hemostasis in an optimal setting, in
casu (i) a representative donor-derived PTC model, (ii) clinically relevant CNI exposure, and
(iii) spatiotemporal detection of the glutathione redox balance in real-time, we demonstrated
that oxidative stress is not likely to be involved in CNIT on PTC level.
Supporting information
S1 Fig. Mitochondrial and cytosolic glutathione redox state in ciPTC exposed to hydrogen
peroxide. CiPTC expressing mitochondrial or cytosolic roGFP2 were exposed or not to 1 mM
H2O2 for 15 min. The large and small horizontal lines show the median and standard devia-
tions, respectively. Every individual symbol represents the average ratio of 10 measurements
within one cell (at least 6 randomly chosen cells were analyzed per experiment). The Wilcoxon
test was used to calculate p-values, and statistical differences are marked (�, p< 0.05; ��,
p< 0.01).
(TIF)
S2 Fig. Cytosolic glutathione redox state in ciPTC exposed to a combination of therapeutic
CNI levels and BSO. CiPTC expressing cytosolic roGFP2 were exposed for 48 h to vehicle
(0.1% v/v DMSO), 15 μg/mL of cyclosporin A (CsA), 0.3 μg/mL tacrolimus (Tac), 0.5 mM L-
buthionine-sulfoximine (BSO), or a combination of CsA or Tac with BSO. The large and small
horizontal lines show the median and standard deviations, respectively. Every individual sym-
bol represents the average) ratio of 10 measurements within one cell (at least 9 randomly cho-
sen cells were analyzed per experiment; number of independent experiments: 2). Data were
statistically analyzed using one-way ANOVA, but no significant differences were detected.
(TIF)
S3 Fig. Mitochondrial and cytosolic H2O2 levels in ciPTC exposed to therapeutic CNI con-
centrations for 24 and 48 h. CiPTC expressing mitochondrial or cytosolic roGFP2-Orp1 were
exposed to (A, C) vehicle (0.1% v/v DMSO) or 15 μg/mL of cyclosporin A (CsA) and (B, D)
vehicle or 0.3 μg/mL tacrolimus (Tac). The upper and lower panels summarize the results of 3
and 1 experiment, respectively. The large and small horizontal lines show the median and stan-
dard deviations (as error bars), respectively. Every individual symbol depicts the average ratio
of 10 measurements within one cell (at least 5 randomly chosen cells were analyzed per experi-
ment). One-way ANOVA test was used to calculate p-values: (A) 0.1; (B) 0.1, (C) 0.9; and (D)
0.1.
(TIF)
S4 Fig. Mitochondrial H2O2 levels in ciPTC exposed to supra-therapeutic CNI concentra-
tions. ciPTC expressing mitochondrial roGFP2-Orp1 were exposed for 24 h to vehicle (for
CsA: 0.1% v/v DMSO; for Tac: 0.5% v/v DMSO), 50 μg/mL CsA, or 50 μg/ml Tac. The results
are derived from 3 independent experiments. The large and small horizontal lines show the
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median and standard deviations (as error bars), respectively. Every individual symbol depicts
the average ratio of 10 measurements within one cell (at least 5 randomly chosen cells were
analyzed per experiment). The paired t-test was used to calculate p-values: �, 0.01; non-signifi-
cant (NS), 0.6.
(TIF)
S1 Table. Mean normalized values of the mitochondrial, peroxisomal, and cytosolic
roGFP2-based glutathione redox sensors in ciPTC exposed to calcineurin inhibitors or
hydrogen peroxide. For experimental details, see legend to Fig 1. The percentages represent the
mean 400/480 nm ratiometric response ratios compared to the averages of the corresponding
non-treated control cells, which were set to 100%. Given that peroxisomes have the capacity to
resist oxidative insults generated outside the organelle [1], cells expressing peroxisomal roGFP2
(PO) were not challenged with external H2O2. The Kruskal-Wallis (KW) or One-way ANOVA
(OWA) test were used to calculate p-values. C, cytosolic roGFP2; ciPTC, conditionally immor-
talized proximal tubule cell; CsA, cyclosporin A; MT, mitochondrial roGFP2; Tac, tacrolimus.
(PDF)
S2 Table. Quantitative analyses of mitochondrial morphology in ciPTC under CNI.
(PDF)
S3 Table. Details of the articles studying ROS production in response to CNI in PTC with
different origins.
(PDF)
S4 Table. Mean normalized values of the mitochondrial and cytosolic roGFP2-Orp1-based
H2O2 sensors in ciPTC exposed to calcineurin inhibitors or hydrogen peroxide. For experi-
mental details, see legend to Fig 1. The percentages represent the mean 400/480 nm ratio-
metric response ratios compared to the averages of the corresponding non-treated control
cells, which were set to 100%. Given that, under basal conditions, peroxisomal roGFP2-Orp1
is almost fully oxidized in ciPTC, this sensor was not included in this analysis. One-way
ANOVA (OWA) test were used to calculate p-values for more than 2 groups. Paired t-test
(PPT) and Wilcoxon test (WT) were used to calculate the difference between 2 groups. C, cyto-
solic roGFP2; ciPTC, conditionally immortalized proximal tubule cell; CsA, cyclosporin A;
MT, mitochondrial roGFP2; Tac, tacrolimus.
(PDF)
S1 References. References cited in S3 Table.
(PDF)
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Supervision: Noël Knops, Lambert P. van den Heuvel, Marc Fransen.
Validation: Yasaman Ramazani.
Visualization: Yasaman Ramazani.
Writing – original draft: Yasaman Ramazani, Dirk J. Kuypers, Elena Levtchenko, Lambert P.
van den Heuvel, Marc Fransen.
Writing – review & editing: Yasaman Ramazani, Noël Knops, Celien Lismont, Lambert P.
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